Navigation Links
InspireMD Reports Financial Results For Period Ended March 31, 2013
Date:5/8/2013

ximately $2.5 million, compared to $10.3 million at June 30, 2012. On April 16, 2013, the Company completed an underwritten public stock offering, providing net proceeds of approximately $22.6 million.

Key Activities; March 31, 2013 PeriodAlan Milinazzo, a 15-year veteran of the interventional cardiology industry, joined InspireMD on January 3rd as President, Chief Executive Officer and a member of the board. Mr. Milinazzo was instrumental in the launch of ENDEAVOR, Medtronic, Inc.'s first drug eluting stent platform which has since generated more than $1 billion in revenue. He previously spent 12 years in executive positions at Boston Scientific Corporation, another major stent producer, serving as Vice President of Marketing at its $200 million SCIMED European unit, responsible for product launches, clinical programs and regulatory strategies. Most recently he served as President and Chief Executive Officer of Nasdaq-listed Orthofix International N.V., a position he was promoted to in 2006 after being hired a year earlier as Chief Operating Officer. During his tenure at Orthofix, he transformed it into a category leader in novel spine and orthopedic stem cell therapy. Total company revenue grew from $300 million to $580 million and profits nearly doubled.

Since joining InspireMD, he has been instrumental in completing a $25 million equity raise, and in leading the creation of new sales, marketing and corporate strategies; goals and programs intended to position the Company for near and long-term growth as a leader in the worldwide stent market.

--The Company continues to strengthen its commercial activities with an expanded sales and marketing organization and new distributor relationships, in order to leverage the MASTER I trial's initial outcomes, MGuard EPS product line expansions and new regulatory approvals.

--Michael Berman, a former Group President and Executive Committee member of Boston Scientific, joined InspireMD's
'/>"/>

SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. InspireMD Receives Approval From US Food and Drug Administration to Begin US Regulatory Trial
2. InspireMD Closes $25 Million Underwritten Public Offering
3. InspireMD Announces Pricing of Underwritten Public Offering of Common Stock and Listing on NYSE MKT
4. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
5. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
6. InspireMD Reports Results for Period Ended Dec. 31, 2012
7. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
8. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
9. InspireMD Reports Results For Period Ending Sept. 30, 2012
10. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
11. InspireMD to Present at Harvard Investors Group on June 27 in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Inc. (NYSE: RMD ) today announced results for ... 30, 2014.  Revenue for the quarter was $415.2 million, flat ... percent decrease on a constant currency basis). Net income was ... quarter ended June 30, 2013. Diluted earnings per share for ... to the quarter ended June 30, 2013.  ...
(Date:7/31/2014)... Inc. (the "Company") (Nasdaq: PCYC ) today reported ... 30, 2014. Financial Results for the Six Months ... for the quarter ended June 30, 2014 increased to $113.0 ... 2013 primarily due to IMBRUVICA ® (ibrutinib) net product ... the six months ended June 30, 2014 increased to $232.4 ...
(Date:7/31/2014)... MOUNTAIN VIEW, Calif. , July 31, 2014 ... ) today provided an update on its pipeline ... of 2014, Alexza expects to initiate a Phase ... which is being developed for the management of ... identified two new Staccato -based product candidates ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24
(Date:8/1/2014)... (PRWEB) August 01, 2014 Millions of ... affects the legs and in some cases the arms, ... state that about 17 million women in the U.S. ... women dealing with the pain, embarrassment and discomfort caused ... even some physicians are unaware that this is a disease,” ...
(Date:8/1/2014)... August 01, 2014 Get the report ... with PitchBook presents the 3Q 2014 Private Equity Breakdown ... equity investment, exits and fundraising activity in the second ... help plan for private equity endeavors for the remainder ... to download it now. , About Merrill DataSite , ...
(Date:7/31/2014)... The 2013 edition of the ... listings, appellate decisions, litigation and settlement trends, trials, ... with California's Proposition 65. , The Handbook is ... history and trends impacting California's Proposition 65. ... the series which adds approximately 200 pages devoted ...
(Date:7/31/2014)... Women who recently used birth control pills containing ... increased risk for breast cancer, whereas women using some ... Cancer Research , a journal of the American ... use of contemporary oral contraceptives [birth control pills] in ... cancer risk relative to never or former oral contraceptive ...
(Date:7/31/2014)... July 31, 2014 Leelanau Peninsula’s newest winery, ... 3, 2014 at 7788 East Horn Road in Lake Leelanau. ... Trail , Aurora Cellars is the 25th winery along the ... the popular wine tour events, making its trail event debut ... 2014. , Owners David and Faye Mathia opened the ...
Breaking Medicine News(10 mins):Health News:Lipedema Centers Works With Insurers To Gain Coverage For Lipedema Treatment 2Health News:Register to Download Merrill DataSite's Report: PitchBook 3Q 2014 Private Equity Breakdown Report 2Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2Health News:Recent use of some birth control pills may increase breast cancer risk 2Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2
... ... Model 362 portable spa to the Eagle Condor Humanitarian foundation to benefit several impoverished villages ... (Vocus) ... a Model 362 portable hot tub for auction at a fundraising event for ...
... ... pleased to announce that Aaron Alsop has achieved the Project Management Professional (PMP) ... ... DTM Systems Corporation is pleased to announce that Aaron Alsop has achieved the ...
... ... Creation Processes , ... Naples, FL (PRWEB) July 8, 2010 -- QualEDIx, a leading provider of HIPAA ... AgilEDIx, a real-time HIPAA 5010 and ICD-10 test data generation and management service. ...
... (CF) recover from exacerbations equally well if they are ... researchers from Johns Hopkins University. Furthermore, longer treatment with ... over shorter courses. The study was published ... Thoracic Society,s American Journal of Respiratory and Critical ...
... Study suggests that physical activity has little if any role ... the key factor behind diabetes, heart disease and some cancers. ... Plymouth, UK, and has been observing in detail a cohort ... A review published in 2009 of all trials using physical ...
... HealthDay Reporter , WEDNESDAY, July 7 (HealthDay News) ... United States is likely to last through the weekend, taxing ... and air conditioning and fans up and running. And ... only making matters worse, meteorologists say. On Tuesday, ...
Cached Medicine News:Health News:Another Reason to Buy a Hot Tub: Bullfrog Donates Spa to Humanitarian Effort 2Health News:Another Reason to Buy a Hot Tub: Bullfrog Donates Spa to Humanitarian Effort 3Health News:DTM Systems Is Pleased To Announce That Aaron Alsop Has Achieved The Project Management Professional Credential With The Project Management Institute 2Health News:QualEDIx Announces the Launch of the Nation's Only Managed Service Model for HIPAA 5010 and ICD-10 Testing 2Health News:Home care equivalent to hospital care for some patients with cystic fibrosis 2Health News:Home care equivalent to hospital care for some patients with cystic fibrosis 3Health News:Inactivity 'no contributor' to childhood obesity epidemic 2Health News:Relentless Heat Threatens Your Health 2Health News:Relentless Heat Threatens Your Health 3Health News:Relentless Heat Threatens Your Health 4
... Focus Diagnostics HerpeSelect® 1 ELISA IgG ... or absence of human IgG class antibodies ... the Focus HerpeSelect® 2 ELISA IgG, the ... or expectant mothers for aiding in the ...
Perfect for loading small volume samples onto agarose and polyacrylamide gels....
Conducting disposable filter-tips....
Designed to fit a variety of 250 L and 300 ul multi-channel pipettors, this tip offers a secure fit and extra space for repeat pipetting....
Medicine Products: